US89377M1099 - Common Stock - After market: 74.69 0 (0%)
NASDAQ:TMDX (3/28/2023, 7:00:02 PM)-1.18 (-1.56%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 212 full-time employees. The company went IPO on 2019-05-02. The firm is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed an organ care system (OCS), a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company designed its OCS technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state. The company has developed three OCS products, one each for lung, heart and liver transplantation. Its products include OCS Lung, OCS Heart, and OCS Liver. Its OCS product consists of three components customized for each organ, which include the OCS Console, OCS Perfusion Set and OCS Solutions. The company is also developing OCS products for additional organs, including kidneys.
TRANSMEDICS GROUP INC
200 Minuteman Road
Andover MASSACHUSETTS 01810
P: 19785520900.0
CEO: Waleed H. Hassanein
Employees: 212
Website: https://www.transmedics.com/
Patient investors who would like to see their investments rise 10x have some interesting options right now.
/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
This is more than just a medical device manufacturer.
There was much for investors to like in the company's latest earnings report.
/PRNewswire/ - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
Here you can normally see the latest stock twits on TMDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: